[go: up one dir, main page]

ES2052114T3 - Composicion farmaceutica altamente absorbible. - Google Patents

Composicion farmaceutica altamente absorbible.

Info

Publication number
ES2052114T3
ES2052114T3 ES90114268T ES90114268T ES2052114T3 ES 2052114 T3 ES2052114 T3 ES 2052114T3 ES 90114268 T ES90114268 T ES 90114268T ES 90114268 T ES90114268 T ES 90114268T ES 2052114 T3 ES2052114 T3 ES 2052114T3
Authority
ES
Spain
Prior art keywords
pharmaceutical composition
compound
highly absorbable
absorbable pharmaceutical
propenil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90114268T
Other languages
English (en)
Inventor
Yoshihiro Ishizue
Kozo Ishida
Masaaki Odomi
Toru Nishibayashi
Kazuo Koshino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2052114T3 publication Critical patent/ES2052114T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE PRESENTA UN COMPUESTO FARMACEUTICO QUE CONTIENE COMO INGREDIENTE ACTIVO, 1,4-DIHIDRO-2,6-DIMETIL-4-(3-NITROFENIL)PIRIDINA DE 3-FENIL-2(E)-PROPENIL (DESDE ESTE MOMENTO REFERENCIADO COMO "EL COMPUESTO DEL PRESENTE INVENTO") EN LA FORMA DE ESTADO AMORFO CON UN PH QUE DEPENDE DEL TIPO DE ACIDO METACRILICO Y SUS COPOLIMEROS DERIVADOS PARA, DE ESTA MANERA, MEJORAR LA ABSORCION DEL COMPUESTO DEL INVENTO A TRAVES DEL TRACTO GASTROINTESTINAL CUANDO EL COMPUESTO SE ADMINISTRA ORALMENTE. EL COMPUESTO DEL INVENTO TIENE ACTIVIDADES FARMACOLOGICAS, COMO POR EJ. EFECTO ANTIHIPERTENSIVOS.
ES90114268T 1989-07-25 1990-07-25 Composicion farmaceutica altamente absorbible. Expired - Lifetime ES2052114T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP19241389 1989-07-25

Publications (1)

Publication Number Publication Date
ES2052114T3 true ES2052114T3 (es) 1994-07-01

Family

ID=16290907

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90114268T Expired - Lifetime ES2052114T3 (es) 1989-07-25 1990-07-25 Composicion farmaceutica altamente absorbible.

Country Status (6)

Country Link
EP (1) EP0410422B1 (es)
JP (1) JPH0729926B2 (es)
KR (1) KR0151157B1 (es)
DE (1) DE69006963T2 (es)
DK (1) DK0410422T3 (es)
ES (1) ES2052114T3 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW212139B (es) * 1991-04-15 1993-09-01 Yamanouchi Pharma Co Ltd
GB9200607D0 (en) * 1992-01-13 1992-03-11 Ethical Pharma Ltd Pharmaceutical compositions containing nifedipine and process for the preparation thereof
IT1255792B (it) * 1992-08-05 1995-11-16 Bayer Italia Spa Composizioni farmaceutiche per la somministrazione orale di diidropiridine in forma di bevanda
EP0896823B1 (en) * 1997-07-15 2002-09-25 Development Center For Biotechnology Improved stabilization of Misoprostol
US6337091B1 (en) 1997-10-27 2002-01-08 Temple University - Of The Commonwealth System Of Higher Education Matrix for controlled delivery of highly soluble pharmaceutical agents
US6350786B1 (en) † 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
GB0102342D0 (en) * 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
FR2841138B1 (fr) * 2002-06-25 2005-02-25 Cll Pharma Composition pharmaceutique solide contenant un principe actif lipophile, son procede de preparation
DE10260921A1 (de) * 2002-12-20 2004-07-01 Röhm GmbH & Co. KG Verfahren zum Überziehen von Substraten für pharmazeutische Anwendungen mit einem Gemisch aus zwei filmbildenden Überzugsmitteln
TW200539903A (en) 2004-03-12 2005-12-16 Smithkline Beecham Plc Pharmaceutical formulations
US20070238942A1 (en) * 2006-04-10 2007-10-11 Esophamet Corp. Apparatus and method for detecting gastroesophageal reflux disease (gerd)
JPWO2023182332A1 (es) * 2022-03-22 2023-09-28

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61140567A (ja) * 1984-12-13 1986-06-27 Otsuka Pharmaceut Co Ltd ジヒドロピリジン誘導体
JPS61227524A (ja) * 1985-03-30 1986-10-09 Tooa Eiyoo Kk プラゾシン製剤及びその製法
IL81419A0 (en) * 1986-01-30 1987-08-31 Syntex Inc Long acting sustained release pharmaceutical compositions containing dihydropyridines and their preparation

Also Published As

Publication number Publication date
KR0151157B1 (ko) 1998-10-15
DK0410422T3 (da) 1994-04-11
JPH0729926B2 (ja) 1995-04-05
EP0410422B1 (en) 1994-03-02
JPH03130225A (ja) 1991-06-04
EP0410422A3 (en) 1991-06-05
KR910002429A (ko) 1991-02-25
DE69006963D1 (de) 1994-04-07
EP0410422A2 (en) 1991-01-30
DE69006963T2 (de) 1994-07-14

Similar Documents

Publication Publication Date Title
ES2052114T3 (es) Composicion farmaceutica altamente absorbible.
GT199900203A (es) Composiciones de celecoxib.
IT1260505B (it) Sistemi farmaceutici orali a cessione ritardata per il rilascio specifico nel colon
BR0007445A (pt) Composições tendo fornecimento aperfeiçoado de ingredientes ativos
IT1250421B (it) Composizione farmaceutica a rilascio controllato con proprieta' bio-adesive.
BR0014441A (pt) Composições que apresentam estabilidade aperfeiçoada
EA200700049A1 (ru) Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
BR9907866A (pt) Composição farmacêutica compreendendo uma combinação de metformina e fibrato, e seu uso para a preparação de medicinas destinadas a reduzir a hiperglicemia
GEP20043315B (en) Non-Peptide GnRH Agents, Methods For Their Preparation and Use Thereof
BRPI0611400A8 (pt) Formulações contendo xiloglicano muco-adesivas úteis em dispositivos médicos e em formulações farmacêuticas
CO5271728A1 (es) Forma de dosificacion de farmaco en capas impulsadas por hidrogel
ES2110212T3 (es) Composicion farmaceutica efervescente que contiene ibuprofeno y su procedimiento de preparacion.
ES2178048T3 (es) Uso de rifaximina como medicamento para el tratamiento de diarrea por criptosporidiosis.
PE28397A1 (es) Soluciones salinas no inorganicas para administracion endonasal
PT96506A (pt) Processo para a preparacao de composicoes orais que incorporam como ingrediente activo pimobendano
ES2050363T3 (es) Sistema para la liberacion intraoral de medicamento.
BR9908617A (pt) Nitroto inorgânico e ácido orgânico em combinação como uma composição antiviral tópica.
CA2547990A1 (en) Pharmaceutical compositions and methods for insulin treatment
BR9910407A (pt) Dispositivo de apresentação
IT1303671B1 (it) Sali dell'acido nitrico con farmaci attivi nel trattamento dipatologie del sistema respiratorio
CO5050328A1 (es) Sistema solvente para la mejor penetracion de compuestos farmaceuticos
ES8700232A1 (es) Un procedimiento para producir 1a,25-dihidroxi-26,27-dime- tilcolecalciferol
ATE303137T1 (de) Pharmazeutische zusammensetzung zur orale verabreichung mit verbesserter bioverfügbarkeit
ES2169223T3 (es) Substancia anticancerosa que inhibe la metastasis cancerosa.
BR0113148A (pt) Composições de 2-piridinamina e métodos relacionados

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 410422

Country of ref document: ES